Drug Trial Radar · NCT00362895
A Bioequivalence Study of Tobradex AF
Last checked: Nov 19, 2026Latest source record: Mar 5, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
995
Actual
Start
Apr 2006
Primary completion
Aug 2006
Study completion Aug 2006
Sponsor
- Lead sponsor
- Alcon ResearchIndustry
- Sponsor type
- Industry
- First posted
- Aug 15, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to determine the amount of study medication that moves from the front of the eye into the fluid at the front of the inside of the eye.
Conditions
- Cataract
Interventions
Tobramycin 0.3% / Dexamethasone 0.033% ophthalmic suspensionDrug
One drop in the study eye, single dose
Tobramycin 0.3% / Dexamethasone 0.1% ophthalmic suspension (TOBRADEX)Drug
One drop in the study eye, single dose
Primary outcomes
What the sponsor says the trial is designed to measure.
- Concentration of dexamethasone in aqueous humor following a single topical ocular administration
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Contact Alcon for Trial Location(s)
Fort Worth, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.